EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective�…
Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
K Chen, G Cheng, F Zhang, G Zhu, Y Xu, X Yu…�- Lung Cancer, 2020 - Elsevier
Objectives The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with�…
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with�…
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
ZY Dong, JT Zhang, SY Liu, J Su, C Zhang, Z Xie…�- …, 2017 - Taylor & Francis
Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying�…
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying�…
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
Y Yoneshima, K Ijichi, S Anai, K Ota, K Otsubo…�- Lung Cancer, 2018 - Elsevier
Objectives Expression of programmed cell death–ligand 1 (PD-L1) has been associated
with clinical outcome of programmed cell death–1 (PD-1) pathway blockade in non–small�…
with clinical outcome of programmed cell death–1 (PD-1) pathway blockade in non–small�…
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
S Liu, Z Dong, S Wu, Z Xie, L Yan, YF Li, H Yan, J Su…�- Lung Cancer, 2018 - Elsevier
Objectives EGFR-mutated or ALK-rearranged non-small cell lung cancer (NSCLC) often
showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports�…
showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports�…
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
K Chen, G Pan, G Cheng, F Zhang, Y Xu…�- Thoracic�…, 2021 - Wiley Online Library
Background Insertions in exon 20 (Ex20ins) of epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and�…
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and�…
[HTML][HTML] The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Methods One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was�…
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was�…
[HTML][HTML] Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC�…
Introduction Epidermal growth factor receptor (EGFR) mutation status was reported to be
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular�…
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular�…
[HTML][HTML] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment.
Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for�…
Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for�…
Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC
X Li, Z Lian, S Wang, L Xing, J Yu�- Cancer letters, 2018 - Elsevier
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-
1/PD-L1) pathway displayed striking and durable clinical responses in patients with non�…
1/PD-L1) pathway displayed striking and durable clinical responses in patients with non�…
Related searches
- egfr mutations alk rearrangements
- response rates alk rearrangements
- response rates egfr mutations
- lung cancer egfr mutation
- pathway blockade alk rearrangements
- pathway blockade egfr mutations
- pd l1 alk rearrangements
- pd l1 egfr mutations
- response rates pathway blockade
- pd l1 lung cancer
- lung adenocarcinoma alk rearrangements
- lung cancer cells infiltration
- lung cancer clinical relevance
- uninflamed phenotype egfr mutation
- weak immunogenicity egfr mutation
- retrospective analysis alk rearrangements